Core Insights - CareDx, Inc. announced pivotal clinical validation results for AlloHeme™, a non-invasive, next-generation sequencing (NGS) and AI-powered monitoring test aimed at predicting relapse in transplant patients [1] Company Overview - CareDx, Inc. is recognized as a leading precision medicine company focused on developing high-value healthcare solutions specifically for transplant patients and their caregivers [1]

Core Insights - CareDx, Inc. is a leading precision medicine company focused on healthcare solutions for transplant patients and caregivers [1] Group 1 - The company announced pivotal clinical validation data from the ACROBAT study (NCT04635384) [1] - This data will be presented at the 2026 Tandem Meetings, Transplantation & Cellular Therapy Meetings of ASTCT™ and CIBMTR® [1]